Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Mar 1;16(3):e0247672. doi: 10.1371/journal.pone.0247672

Reference intervals of common clinical biochemistry analytes in young Nigerian adults

Ojor Ayemoba 1,*, Nathan Okeji 1, Nurudeen Hussain 1, Tahir Umar 1, Anthony Ajemba-Life 1, Terfa Kene 2, Uchechukwu Edom 1, Ikechukwu Ogueri 1, Goodluck Nwagbara 1, Inalegwu Ochai 1, Usman Adekanye 1, Ikenna Onoh 3
Editor: Ulrike Gertrud Munderloh4
PMCID: PMC7920356  PMID: 33647019

Abstract

Background

Reference intervals are assessment tools for interpretation of clinical test results. These intervals describe the dispersion of test parameter values of apparently healthy persons in defined populations as health status indicators. Using reference intervals obtained and validated in populations outside the geographical region of derivation for medical decision-making may impact negatively on clinical interpretation and patient management. Many countries have established their reference values, current studies on these data for Nigeria are however scarce. Determination of clinical biochemistry reference intervals for young Nigerian adults which is of particular importance in routine clinical management and conduct of clinical trials in response to existing and emerging diseases will add significantly to the existing body of knowledge.

Objective

The objective was to establish reference intervals for 24biochemistry analytes among Nigerians aged 18 to 26 years.

Methods

This was a cross-sectional study among 7,797 consenting male and female military applicants aged 18 to 26 years from 37 States of Nigeria. It was a total study among volunteers for military service. Blood samples were collected and subjected to serological testing for HIV-1 and 2, hepatitis-B, malaria, pregnancy and haematuria to restrict our study population to apparently healthy participants. Biochemical assays were performed on 6,169 participant samples that met the inclusion criteria. Generated data was entered into MS Excel® and exported into SPSS® software version 16 for analysis. Statistical tools used were frequencies, median, mid 95th percentile range with 2.5th and 97.5th percentiles as limits. Reference intervals were estimated using nonparametric methods. No intergender statistical comparison was made.

Results

Complete records were obtained for 6,169 eligible participants. Median values and associated reference intervals were similar in both genders.

Conclusion

The findings from this study will help in clinical decision-making and play a significant role in supporting the current global rapid expansion of clinical trials in response to the urgent need for preventive and therapeutic solutions to existing and emerging diseases.

Introduction

Reference intervals are assessment tools for interpretation of clinical test results. These intervals describe the dispersion of test parameter values of apparently healthy persons in defined populations as health status indicators. These limits have been described as the most common decision support tool in laboratory medicine and the inclusion of reference intervals in a pathology report is endorsed by the international clinical laboratory standard ISO 15189, recommended by the Clinical and Laboratory Standard Institute (CSLI) and required by the College of American Pathologists (CAP), [14]. Though individuals could appear healthy, identification of appropriate biological markers and prevalent diseases in the population is necessary prior to determining laboratory reference intervals [3].

The use of reference intervals derived and validated in populations outside the region of application for medical decision-making and intervention could be misleading and may impact negatively on clinical management of patients or clients [1, 3]. Locally-generated laboratory reference intervals are therefore necessary for accurate diagnosis of medical disorders, disease staging, treatment monitoring, clinical trials and medical research in general. Many countries in Europe, America and Asia have established their national laboratory reference values [57]. However, studies from African countries are fragmented with no nationally established reference intervals. Available African reference ranges, though fragmented, have shown variation of biochemical and haematological values when compared to reference intervals validated in Western populations [815].

As a result of this, biochemical reference intervals commonly used in Nigeria are based on values obtained from Western-derived literature or laboratory test-kit inserts. Most available Nigerian studies on reference intervals are hospital-based or conducted on sub-regional and regional populations [8, 10, 15]. Studies of biochemical reference intervals on a truly nationally representative apparently healthy Nigerian population are unavailable. This study, which covered all the 36 States of Nigeria and the Federal Capital Territory, seeks to establish the national clinical biochemistry reference intervals among young adult Nigerians who applied for military service. It also reviews the reference intervals derived from this study with those obtained from predominantly Western cohorts in Europe and North America [16, 17].

Materials and methods

Study area

Nigeria is located in West Africa. The population of Nigeria is estimated to be about 206 million while the age group 18–26 years constitute about 15.9% (33 million) [18]. It is made up of 36 states and the Federal Capital Territory.

Study design and study population

This was a cross-sectional study among a population of young Nigerian adult volunteers that applied for military service between March and October 2014. The study population comprised of adult male and female Nigerians within the age group eighteen to twenty-six years old, from all the 36 Nigerian states and the Federal Capital Territory. The total population of military applicants who gave informed consent were considered eligible for this study. However, some were excluded based on the following pre-determined exclusion criteria:

  1. Presence of antibodies against the Human Immuno-deficiency virus (HIV)

  2. Presence of surface antigen to Hepatitis B virus in plasma

  3. Serological reactivity to Plasmodium species in plasma samples.

  4. Reactivity of females to plasma B-HCG as an indication for pregnancy.

  5. Presence of glycosuria, proteinuria, haematuria and bilirubinuria.

Out of 7,797 volunteers, a total of 1,628 were excluded. According to CLSI and IFCC recommendations, studies aimed at establishing Reference Intervals should have a minimum of 120 healthy participants in each category of the grouping variable [3, 13]. With the enrolment of 5932 males and 237 females, this requirement was exceeded in our study. All participants were apparently healthy young people from age 18 to 26 years from all states and the Federal Capital Territory in Nigeria.

Specimen collection and rapid testing for biomarkers

Blood samples (14.5mls) were collected from each eligible participant for laboratory analysis, using rapid diagnostic tests to detect serological markers of infection or pregnancy. Plasma obtained from 4.5 mls of whole blood collected in EDTA bottles was used for serological testing while serum, obtained from 10 mls of blood collected in serum separator tubes (SST) was used for biochemical analysis after centrifugation. Rapid testing for HIV-1 & 2 was performed using the Nigerian national HIV serial testing algorithm (Determine®, Unigold® and Stat-Pak®); HBsAg sero-positivity and pregnancy status were determined using LabACON® kits (Citus Diagnostic Inc, British Columbia, Canada) while malaria infection screening was performed using SD BIOLINE® rapid diagnostic test kit (Standard Diagnostics Inc, Korea). Combi-9® urinalysis rapid test kit (Machery-Nagel GmbH & Co-KG, Duren, Germany) was used to detect haematuria. All assays were performed in accordance with product manufacturers’ guidelines. Rapid testing for infection biomarkers was performed within 6 hours of sample collection.

Biochemical analysis

Biochemical analysis was conducted on serum samples, extracted from 10 mls of blood, and stored at -80°C in the Defence Reference Laboratory, Abuja, using Selectra Pro-S® automated clinical chemistry analyzer (Vital Scientific, Elitech Group Company, Netherlands). Assays performed included liver function tests (Total Serum Proteins, Albumin, Serum Globulin, alanine transaminase (ALT), aspartate transaminase (AST), Alkaline Phosphatase, gammaglutamyl transferase (GGT), Total Bilirubin, Direct and Indirect Bilirubin, Urea, Creatinine, Electrolytes (Na, K, Cl), Lipid profile (Total Cholesterols, HDL, LDL Cholesterols and Triglycerides), Calcium, Phosphate, Uric Acid, serum Lactate and serum Amylase). The auto-analyzer could not provide the results for all parameters in all the specimens (N) leading to missing values for some parameters. The analytical principles utilized for estimating the electrolytes are as shown in Table 1.

Table 1. Analytical principles used for clinical biomarker estimation.

S/No Analyte Analytical principle
1. Sodium (Na) (mmol/L) Dry ISE (Indirect Ion Selective Electrode)
2. Potassium (K) (mmol/L) Dry ISE (Indirect Ion Selective Electrode)
3. Chloride (Cl) (mmol/L) Dry ISE (Indirect Ion Selective Electrode)
4. Urea (U) (mmol/L) Enzymatic colorimetric kinetic (Berthelot’s Urease Method)
5. Creatinine (umol/L) Colorimetric Kinetic (Jaffe’s Method).
6. Lactate (mmol/L) Colorimetric Enzymatic Endpoint (Elitech)
7. Phosphate (mmol/L) Colorimetric Endpoint. Phosphomolybdate
8. Uric Acid (umol/L) Colorimetric UV Kinetics (Elitech)
9. Calcium (Ca) (mmol/L) Colorimetric Endpoint ARSENZOIII
10. Gamma GT (UL) Colorimetric UV Kinetics IFCC-GLUPA-C
11. Amylase (U/L) Enzymatic UV Colorimetric (Kinetic) (Elitech)
12. Total Protein (g/l) Colorimetric End Point (Biuret’s method)
13. Albumin (g/l) Colorimetric End point, (Bromocresol Green Colorimetric Dye Binding Method).
14. Total Globulin (g/l) Colorimetric Endpoint. Calculated with reference to Total Protein and Albumin
15. ALT (U/L) Enzymatic UV KINETICS method. IFCC
16. AST (U/L) Enzymatic UV KINETICS method. IFCC
17. Alkaline Phosphatase (U/L) Enzymatic UV Kinetic method IFCC
18. Total Bilirubin (umol/L) Colorimetric End- Point (Modified Malloy and Evelyn)
19. Direct Bilirubin (umol/L) Colorimetric End- Point. (Modified Malloy and Evelyn) Sulfanilic acid method
20. Indirect Bilirubin (umol/L) Colorimetric End- Point. (Modified Malloy and Evelyn) Sulfanilic acid method
21. Total Cholesterol (mmol/L) Enzymatic, colorimetric End point (CHOD-PAP)
22. HDL Cholesterol (mmol/L) Direct Selective Detergent (Elitech)
23. LDL Cholesterol (mmol/L) Direct Selective Detergent (Elitech)
24. Triglycerides (mmol/L) Enzymatic, End point (Elitech)

Quality control

Laboratorians who had consistently passed Competency Testing for at least 3 years prior to study commencement were drawn from the Defence Reference Laboratory (DRL), Abuja, to carry out initial biomarker screening in the field and subsequent biochemical analysis in the DRL. Routine Quality Control (QC) procedures such as equipment/assay validation and use of commercially prepared controls were strictly adhered to. Data confidentiality and quality were ensured through specimen de-identification/aggregation and double entry by 2 independent Data Entry Clerks.

Statistical analysis

Data sets were entered into MS Excel® and exported to SPSS® for analysis. Frequencies and proportions were generated and reference intervals were computed independently for male and female participants. Non-parametric method of analysis was used to generate the measure of central tendency (median) and dispersion (2.5th– 97.5th range) for each biochemical parameter. The results were stratified by gender for each parameter, no statistical comparison was made and therefore no statistical test of significance was required.

Ethical considerations

Ethical approval was obtained from the Nigerian Ministry of Defense Health Research Ethics Committee (MODHREC) Abuja. Written informed consent was obtained from each volunteer followed by HIV pre- and post-test counseling. Participants who tested positive to bio-markers of infection were referred to the nearest care and treatment centre. Personal identifiers were eliminated through the use of unique Study Identification Numbers (SIN).

Results

A total of 6,169 (5,932 males and 237 females) participants were enrolled in this study.

The gender-differentiated and aggregate sample size, median, and 95 percentile reference ranges for selected general biochemical parameters are shown in Table 2. All median values and associated reference ranges are shown for males only, females only and a total figure for both genders. Table 3 shows similar findings for selected liver function and lipid parameters.

Table 2. Statistical analysis of selected general biochemical reference intervals among young adult Nigerians.

Analytes Gender N Median Reference Value (95% Percentile)
Sodium (Na) mmol/L Male (M) 5932 133 114–144
Female (F) 237 133 114–146
M and F 6169 133 114–144
Potassium (K) mmol/L Male 5932 4.0 2.7–7.0
Female 237 4.1 2.8–7.0
M and F 6169 4.0 2.7–7.0
Chloride (Cl) mmol/L Male 5929 93 80–100
Female 237 93 79–100
M and F 6166 93 80–100
Urea (U) mmol/L Male 5931 3.6 1.2–9.0
Female 237 3.4 1.3–7.2
M and F 6168 3.6 1.2–9.0
Creatinine (Cr) umol/L Male 5932 88 46–132
Female 237 90 48–136
M and F 6169 88 46–132
Lactate (L) mmol/L Male 5926 3.2 1.4–8.2
Female 237 3.2 1.0–7.6
M and F 6163 3.2 1.4–8.1
Phosphate (P) mmol/L Male 5930 1.3 0.6–4.8
Female 237 1.3 0.6–4.6
M and F 6167 1.3 0.6–4.7
Uric Acid (UA) umol/L Male 5931 274 141–462
Female 237 273 140–400
M and F 6168 274 141–460
Calcium (Ca) mmol/L Male 5932 2.3 1.6–2.7
Female 237 2.3 1.6–2.6
M and F 6169 2.3 1.6–2.7
Gamma GT (GGT) U/L Male 5899 22 10–55
Female 236 23 11–52
M and F 6135 22 10–55
Amylase (AMYL) U/L Male 5924 58 24–117
Female 237 56 24–116
M and F 6161 58 24–117

Table 3. Statistical analysis of selected liver function and lipid parameters among young adult Nigerians.

Analytes Gender N Median Reference Value (95% Percentile)
Total Protein (TP) g/L Male 5930 79.5 52.2–98.0
Female 237 79.3 54.5–97.4
M and F 6167 79.5 52.3–97.9
Albumin (ALB) g/L Male 5898 45.8 34.8–53.0
Female 237 45.9 33.9–54.2
M and F 6135 45.8 34.8–53.0
Globulin (GLOB) g/L Male 5929 33.0 11.6–52.3
Female 237 33.8 10.3–49.0
M and F 6166 33.0 11.5–51.9
ALT (U/L) Male 5928 16.0 3.5–63.5
Female 237 16.6 4.5–63.0
M and F 6165 16.0 3.5–63.2
AST (U/L) Male 5931 18.3 2.9–52.0
Female 237 19.0 3.2–47.4
M and F 6168 18.3 2.9–51.4
Alkaline Phos (ALP) U/L Male 5926 162 79–338
Female 237 152 86–327
M and F 6163 162 79–338
Total Bilirubin (TBIL) umol/L Male 5932 8.8 1.5–33.8
Female 237 8.9 1.4–41.2
M and F 6169 8.8 1.5–33.8
Direct Bilirubin (DBil) umol/L Male 5932 4.3 0.4–16.9
Female 237 4.3 0.2–19.6
M and F 6169 4.3 0.4–17.0
Indirect Bilirubin (IBILI) umol/L Male 5922 4.0 0.4–16.6
Female 237 4.3 0.4–15.4
M and F 6159 4.0 0.4–16.5
Total Chol (TChol) mmol/L Male 5928 4.0 2.4–6.2
Female 237 4.0 2.2–6.3
M and F 6165 4.0 2.4–6.2
HDL Chol (mmol/L) Male 5932 1.3 0.5–2.7
Female 237 1.2 0.4–2.3
M and F 6169 1.3 0.5–2.7
LDL Chol (mmol/L) Male 5925 2.3 0.8–4.5
Female 236 2.4 0.9–4.7
M and F 6161 2.3 0.8–4.5
Triglycerides (TG) mmol/L Male 5930 0.8 0.5–1.8
Female 237 0.7 0.4–1.6
M and F 6167 0.8 0.5–1.8

The findings in this study are shown against standard Western reference intervals in Tables 4 and 5. Only the 95 percentile interval for combined male and female parameters are listed in Tables 4 and 5 since the comparative Western values were not segregated by gender, except for serum Creatinine, Uric Acid, Gamma GT, Alanine and Aspartate Transaminases. The comparative western values for Total Globulin, Direct Bilirubin and Indirect Bilirubin were not contained in the cited British and American publications.

Table 4. Common clinical biochemistry reference intervals of young Nigerian adults and standard reference values.

Parameters This Study Standard Reference Intervals
Dosso [14] (Ghana) Tietz [16] (American) NHS [17] (British)
Sodium (Na) (mmol/L) 114–144 135–150 137–143 133–146
Potassium (K) (mmol/L) 2.7–7.0 3.6–5.2 3.8–4.9 3.5–5.3
Chloride (Cl) (mmol/L) 80–100 102–114 101–106 95–108
Urea (U) (mmol/L) 1.2–9.0 0.9–5.7 3.3–7.9 2.5–6.5
Creatinine (umol/L): Male 46–132 56–119 80–115 59–104
Female 48–136 47–110 53–97 45–84
Lactate (mmol/L) 1.4–8.1 N/A 1.78–1.88 0.5–2.2
Phosphate (mmol/L) 0.6–4.8 0.7–1.5 0.95–1.52 0.8–1.5
Uric Acid (umol/L): Male 141–462 126–418 218–459 200–430
Female 140–400 83–381 147–366 140–360
Calcium (Ca) (mmol/L) 1.60–2.70 N/A 2.28–2.60 2.20–2.60
Gamma GT (UL): Male 10–55 9–71 12–62 0–60
Female 11–52 6–53 12–38 0–40
Amylase (U/L) 24–117 32–139 31–107 28–100

Comparative Reference Interval sources: References [14, 16, 17].

Table 5. Common biochemical reference intervals for liver function, lipid parameters and standard reference values.

Parameters This Study Standard Reference Intervals
Dosso [14] (Ghana) Tietz [16] (American) NHS [17] (British)
Total Protein (g/l) 52–98 50.6–86.7 65–83 N/A
Albumin (g/l) 35–53 33.0–49.9 46–53 35–50
Total Globulin (g/l) Dec-52 N/A N/A
ALT (U/L) Male 4–63 8–54 18–78 10–50
Female 5–63 6–51 14–41 10–35
AST (U/L) Male Mar-52 17–60 18–54 0–40
Female Mar-47 13–48 18–34 0–32
Alkaline Phosphatase (U/L) 79–338 85–241 50–116 30–130
Total Bilirubin (umol/L) Feb-34 2.9–25.8 3–18 0–21
Direct Bilirubin (umol/L) 0–17 0.8–4.0 N/A N/A
Indirect Bilirubin (umol/L) 0–17 N/A N/A N/A
Total Cholesterol (mmol/L) 2.4–6.2 2.0–5.4 3.0–5.9 0–5.0
HDL Cholestrol (mmol/L) 0.5–2.7 N/A 0.8–1.8 1.2–3.0
LDL Cholesterol (mmol/L) 0.8–4.5 N/A 1.6–4.9 1.0–3.0
Triglycerides (mmol/L) 0.5–1.8 N/A 0.4–2.1 0–1.7

Comparative Reference Interval sources: References [14, 16, 17].

Discussion

This study set out to determine the biochemical reference ranges among young adult Nigerians.

The reference intervals from this study appear generally wider than the western ranges, with consistently lower limits for most parameters. The upper limits for a number of parameters in our study appeared notably higher than the western reference values especially for Potassium, Creatinine, Lactate, Phosphate and Alkaline Phosphatase published in standard works [16, 17, 19]. Although median values and associated reference ranges are apparently similar in most male and female parameters, there appears to be a marked difference between the median values for alkaline phosphatase in both genders even though both reference ranges are in full overlap. The 95 percentile reference limits for Alkaline Phosphatase in our study are much higher than those of comparative Western populations. The range between lower and upper limits is also considerably wider with the finding of 259 against 66 and 100 U/L for American and British populations respectively in this study as reflected in Table 4.

Our findings for all other parameters are generally similar to Western reference intervals [16, 17, 19] except for total globulin and bilirubin (direct and indirect), whose comparative western values were unavailable in the cited studies. The upper reference limit of 7.0 mmol/L for potassium is particularly notable in the young adult participants of this study. This finding cannot be easily attributed to changes in renal excretion due to older age or hormones that regulate its clearance. While the reasons for this are not very clear, similar work done by Miri-Dashe’s group on normal Nigerian adults [8] showed potassium reference ranges of 4.0–7.5 and 4.0–7.7 mmol/L for males and females respectively.

The high reference intervals for creatinine observed in this study may be due to dietary factors and high degree of physical activity that is common among the young adult age group of the participants in this study. The high values obtained for phosphate, lactate and alkaline phosphatase are also consistent with the expected pattern for the young adult age group enrolled in this study. These analytes are related to bone metabolism which is very robust at the age range of the study population [20]. Enzymatic activity levels for alkaline phosphatase, calcium and phosphate have been reported to achieve their highest peak during main bone growth period before a slow decline sets in from puberty [20]. These findings from our study are in keeping with such expected trends.

Nigerian public health laboratories, like most clinical laboratories in Africa, rely on reference intervals obtained from textbooks, instrument manuals and reagent inserts for interpretation of laboratory results [8, 9, 13, 14]. This study has shown decreased lower reference limits and higher upper limits with wider overall reference intervals for most of our study analytes when compared to western values. Since Reference Intervals are intended to inform the clinician that laboratory values within the interval indicate a non-diseased condition [21], the significance of this finding lies in the fact that many young adult Nigerians who would otherwise have been classified as having pathological laboratory results can now have better interpretation of their clinical biochemical tests.

This will also impact positively on the eligibility of study volunteers willing to participate in preventive and therapeutic clinical trials as well as their monitoring for adverse reaction especially in the contemporary era of widespread research into existing and emerging infectious diseases. The results of this study will also serve as benchmark reference intervals for analytes such as globulin fraction, direct and indirect bilirubin which are not readily available for African populations.

Limitations

This study was conducted with volunteers for military service in Nigeria. Due to the rigors of military training and service, these volunteers are expected to be at peak physical condition and optimal health. Therefore, they are likely to be fitter and ‘more’ healthy than other apparently healthy individuals in the general population thus giving rise to a healthy volunteer bias. We however do not consider this to have significantly altered our findings as the values of biochemical parameters in the body are maintained within reasonably defined limits in the absence of significant pathology.

Samples used for this study could not be analyzed immediately after collection due to huge sample size, large number of analytes to be tested and the big geographical size of Nigeria. Samples were stored at -80°C until the time for analysis to maintain specimen integrity. Body mass index (BMI) and other possible confounding factors like smoking habit, alcohol consumption and dietary pattern [9, 14] could not be obtained. Wider age stratification to include children and the elderly group was also not possible limiting the generalizability of findings to these age groups.

Conclusion

This study has met the objective of establishing reference intervals for common biochemistry parameters among young adult Nigerians. This will aid proper clinical decision-making process and play a significant role in supporting the current global rapid expansion of clinical trials in response to the urgent need for preventive and therapeutic solutions to existing and emerging diseases where locally generated reference ranges are of paramount importance. We advocate that similar studies be conducted regularly and on a wider age stratification of participants across the country in an attempt to build a culture of more reliance on locally derived laboratory reference ranges. Confidence in and acceptance of locally generated reference intervals will be facilitated by post-study validation and comparison of flagging rates of the relevant laboratory systems.

Supporting information

S1 File. Author list and contributions.

(DOCX)

S2 File. Biochemistry dataset.

(SAV)

S3 File. MODHREC approval—Jan 2014.

(PDF)

S1 Appendix. Consent form.

(DOCX)

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

The Ministry of Defence Health Implementation Programme provided support in the form of salaries for authors [OA, NO, NH, TU, AA, UE, IO, GN, IO, UA], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.

References

  • 1.Horowitz Gary and Jones Graham R.D. Establishment and Use of Reference Intervals. In: Tietz Textbook of Chemistry and Molecular Diagnostics. Editors: Rifai Nader, Horvath Andrea R and Wittwer Carl T. 6th Ed. Elsevier Inc. 2018. p 170–194. [Google Scholar]
  • 2.International Standards Organization. ISO 15189 medical laboratories-requirements for quality and competence. http://www.iso.org/iso/56115.
  • 3.Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory. P.A. Wayne: CSLI; 3rd ed, 2010. [Google Scholar]
  • 4.CAP checklist: Gen. 41096.2014.
  • 5.Scott MG, Le Grys VA and Klutts JS. Electrolytes and Blood Gases. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Editors: Burtis CA, Asherwood ER and Bruns De. 4th Ed. St Louis: Elsevier Saunders. 2006. p 984–991. [Google Scholar]
  • 6.Xia L, Chen M, Liu M, Tao Z, et al. Nationwide Multicenter reference interval for 28 common Biochemical analytes in China. Medicine, 95(9);e2915. 10.1097/MD.0000000000002915 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sairam S, Damalapalli S, Muthu S, Swaminathan J, Ramesh VA, Sekhar S, et al. Haematological and Biochemical Parameters in apparently healthy Indian population: defining reference intervals. Ind. J. Clin. Biochem. 2014:29(3):290–297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Miri-Dashe T, Osawe S, Tokdung M, Daniel N, Choji RP, Mamman I, et al. Comprehensive Reference Ranges for Haematology and Clinical Chemistry Laboratory Parameters Derived from Normal Nigerian Adults. Plos ONE. 2014;9(5). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kibaya RS, Bautista CT, Sawe FK, Shaffer DN, Sateren WR, et al. Reference Ranges for the Clinical Laboratory derived from a rural population in Kericho, Kenya. Plos ONE. 2008;3(10):e3327. 10.1371/journal.pone.0003327 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Salawu AA, Kareem LO, Akande JO, Oke EO and Ogunro PS. Establishing Population Reference Intervals of some Electrolytes, Urea and Creatinine for Adults in Ogbomosho, South Western Nigeria. 10SR J Dent. Med Sc. 2016;15(1). [Google Scholar]
  • 11.Zeh C, Amomkul PN, Inzaule S, Ondoa P, Oyaro B, et al. Population based biochemistry, immunologic and haematological reference values for adolescents and yound adults in a rural population in Western Kenya. Plos ONE. 2011;6(6). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mekannen Z, Amuamuta A, Mulu W, Yimer A, Zenebe Y, Adem Y, et al. Clinical Chemistry Reference Intervals in young healthy adult population in Gojam zones of Amhara National Regional State, Northwest Ethiopia. Plos ONE. 2017;12(9), e0184665. 10.1371/journal.pone.0184665 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Achila OO, Semere P, AndeMichael D, et al. Biochemistry reference intervals for healthy elderly population in Asmara Eritrea. BMC Research Notes. 2017;10:p748–754. 10.1186/s13104-017-3087-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Dosso DK, Kayan K, Adu-Gyasi D, Kwara E, Ocran J, et al. Haematological and Biochemical Reference Values for Healthy Adults in the Middle Belt of Ghana. Plos ONE. 2012;7(4) e36308. 10.1371/journal.pone.0036308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kasia BE, Orluwene CG, and Mrakpor UBA. Estimation of Reference Intervals for Plasma Amylase in Apparently Healthy Adults of Southern Nigeria. 10SR J. Pharm. 2013;3(9).P13–18. [Google Scholar]
  • 16.Adeli K, Ceriotti F and Nieuwesteeg M. Reference Information for the Clinical Laboratory. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics; Editors: Rifai N, Horvath A and Wittwer C. 6th edition. Elsevier Inc, 2018. P1745–1789. [Google Scholar]
  • 17.Munro J. Clinical Biochemistry Reference Ranges Handbook; NHS Trust. 2017 BIJ-11 Issue 9 (V1.7) 1–17.
  • 18.United Nations Department of Economic and Social Affairs Population Dynamics. World Population Prospects 2019 Data Set: Total population (both sexes combined) by single age, region, subregion and country, annually for 1950–2100.
  • 19.Adeli K, Higgins V, Nieuwsteeg M, Raizman J, Chen Y, Wong S, et al. Biochemical Reference Values across Pediatric, Adult and Geriatric Ages: Establishment of Robust Pediatric and Adult Reference Intervals on the Basis of the Canadian Health Measures Survey. Clinical Chemistry, 2015; 61:8, p1049–1062. 10.1373/clinchem.2015.240515 [DOI] [PubMed] [Google Scholar]
  • 20.Heiduk M, Page I, Kliem C, Abicht K, and Klein G. Paediatric reference intervals determined in ambulatory and hospitalized children and juveniles. Clin Chim Acta, 2009; 406:156–161. 10.1016/j.cca.2009.06.021 [DOI] [PubMed] [Google Scholar]
  • 21.Greg Miller and Gary Horowitz. Reference Intervals: Strengths, Weaknesses, and Challenges. 2016; 62:7. P916–923. [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Ulrike Gertrud Munderloh

13 Oct 2020

PONE-D-20-25237

Reference intervals of common clinical biochemistry analytes in young Nigerian adults

PLOS ONE

Dear Dr. Ayemoba,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Both reviewers have identified multiple problems and missing information in the Methods section of your manuscript. Additionally, the statistical analyses need to be reviewed. Be sure to have your manuscript edited by a native English speaking scientist.

Please submit your revised manuscript by Nov 27 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Ulrike Gertrud Munderloh, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Financial Disclosure section:

'This study was funded by the Nigerian Ministry of Defence Health Implementation Programme, No 4B Ikole Street, Area 11, Abuja, FCT, Nigeria. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript'

We note that one or more of the authors are employed by a commercial company: Ave Health Sense Ltd.

a. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

b. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

c. Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. Abstract, methods: You stated the performed tests was “to eliminate possible confounding conditions”, but I think it was rather to select apparently healthy individuals. In addition, this section did not include other major components of methods and materials section like study period, sampling technique, statistical tools, etc.

2. Abstract, results: The third statement is not relevant, better to remove it.

3. Sample size: I think your sample size was 6,169 not 8,505.

4. Introduction (1st paragraph): Please combine the separately written idea as 1, 2, 3, 4. The message is similar.

5. Introduction (paragraph 2, line 6). Are you confident to conclude as many African countries have established their own RI? Please justify your conclusion through evidence. There are some fragmented studies but it is difficult to conclude.

6. Introduction: This portion did not clearly show the gap (such as factors affecting RI not included). Is national RI recommended in such multiethnic country like Nigeria?

7. Materials and methods: You have to follow scientifically accepted guidelines in order to recruit apparently healthy participants. There is no sampling technique mentioned in the document. How did you check the data distribution and partition?

8. Result: The first paragraph should be removed and incorporated in materials and methods section.

9. Result, 2nd paragraph, last statement and 3rd paragraph, 4th and 5ith statement: Interpretation of data is not recommended. Data should be interpreted in the discussion section.

10. Result: I think the RI of females is dominated by males due to large sample size. How could you justify this?

11. Result: Table 3&4: You try to compare your result with American and British studies only. You have to include studies in Africa, Asia, Latin, Etc. Besides, the American study is a text book study which is not appropriate. What was your base (statistics) for comparison? it is not included in materials and methods section.

12. Discussion: Which statistics you computed indicated to say ‘wider’, ‘lower’, ‘higher’ and ‘in concordance’? The discussion section is not supported by statistics and evidences done worldwide.

13. Conclusion: It is out of your result.

Reviewer #2: I congratulate the authors for established RIs for Nigerian Adults and have country specific RIs. However, I do have a few comments for the authors which I believe will improve the manuscript.

Abstract:

Reference intervals are not quantitative data. These are assessment tool to interpret test results.

Please mention the number of analytes for which reference intervals were established and age of the participants clearly in the objective instead of "young Nigerian Adults".

In the method, the authors mentioned that the samples were drawn form 36 state and Territory. However, in the methods section of the paper, the authors mentioned that these participants were volunteers who applied for military services. So the samples were not drawn? Please be consistent.

Please revise the sentence "RIs of common clinical biochemistry analytes were computed." to "RIS were estimated using nonparametric methods."

Results. "No statistical comparison was made" should be in the methods. This is not a result.

Introduction:

This is now well established that RIs are not an indicator of good health or disease unlike clinical decision limit. RIs simply indicate that certain percentage of people within a range. The comment made in the abstract about quantitative data also apply. Please revise the 1st sentence.

How is the volunteers who applied for military service representative of the 18 - 26 year population in Nigeria?

what is the justification of comparing the RIs with western cohorts in Europe and North America but not the RIs currently used in Nigeria?

Methods:

The description of Nigeria may not be necessary as part of the Study Area. Instead of total population I would report the 18 - 26 years old population to who these RIs are applicable.

I don't think the study was design prospectively and desired number of sample was determined. In fact, the study used the data available from the screening process. So the sample size determination may not be appropriate. I would advise the authors to move this point to the discussion expressing that you have more sample than what is recommended.

Biochemical Analysis: Please mention the analytical principle used for each of these biomarkers either as part of the paper or as supplementary. This information will be use for the laboratories who wish to use the RIs knowing there is variation in reference values between analysers/instruments.

Statistical analysis:

Have the authors excluded any outliers? If yes, please explain what method was applied. If not, please justify who not. This is an important step of the statistical analysis.

The authors should clearly mention what method was used for analysis. Measures of Central Tendency include Mean, Median, Mode etc. and deviation can be range, SD, Variance etc. I understand the authors have used median and 2.5th and 97.5th centile which is defined as nonparametric method by CLSI. So this should be clearly mentioned.

Please report the 95% CIs of the RIs. This has also been recommend in recent publications.

What method was applied to compare the established RIs with western countries? Visual? by considering with 95% CI of the established RIs include western countries' RIs?

Results:

Why the auto-analyser could not provide results for all parameters?

Considering the biochemistry analytes are associated with age in the paediatric population i.e. age 0 - <18, is there any association with age? The authors should include scatter plot of analytes across age by sex in the supplementary for the readers to understand age-specific RIs were not necessary for the young adult.

One of the concern I have is the unequal distribution of sexes in the sample. Overall only 237 samples were female. Hence, the RIs of male will be more precise compared to female.

Discussion & Conclusion: While the authors advocate for similar studies, validation or comparison of flagging rate would be another important step in ensuring the RIs are adopted by local laboratories.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 1;16(3):e0247672. doi: 10.1371/journal.pone.0247672.r002

Author response to Decision Letter 0


21 Jan 2021

19th January 2021

Rebuttal Letter to PLOS ONE

Response to Reviewers

Dear Ulrike Gertrud Munderloh,

Thank you for the careful review of our manuscript. After careful consideration of the reviews, I hereby write this rebuttal letter to respond to the points and comments raised by the reviewers. A revised version of the manuscript and the track changes are attached as annexes I and II.

We would like to bring to your attention a typographical error with respect to the number of volunteers who were initially considered for the study. The correct figure is 7,797 as opposed to 8,505 in earlier versions of the manuscript. This has been corrected in the submitted manuscript and did not affect the final number of volunteers eventually enrolled (6,169) nor the final results presented.

The following are the responses to the points raised by the reviewers:

We note that one or more of the authors are employed by a commercial company: Ave Health Sense Ltd.

Response: At the point of conceptualization and implementation of the field activities, the author was a staff of US Department of Defence Walter Reed Programme in Nigeria, which is one of our affiliate organizations.

The author works part-time with Ave Health Sense Ltd which is his current fixed address for delivery of physical mails.

He contributed in the past to protocol development and field data collection. He more recently contributed to data extraction, analysis and writing of the manuscript in his personal capacity.

Ave Health Sense Ltd has NOT contributed funding for the research in whatever including but not limited to payment of salaries.

Also, Dr Ikenna Onoh, who is one of the authors, is a Nigerian Filed Epidemiology Laboratory Training Programme (NFELTP) resident attached to Ministry of Defence Health Implementation Programme as part of his field training. There are no financial obligations to his participation in this study.

a. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Response: There are no commercial affiliations with any organization in the funding of this study.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

Response: “The Ministry of Defence Health Implementation Programme provided support in the form of salaries for authors [OA, NO, NH, TU, AA, UE, IO, GN, IO, UA], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

Response: “There are no commercial affiliations in the funding of this study”

Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Response: "TK is affiliated with Ave Health Sense Ltd. There are no patents, products in development or marketed products to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no commercial affiliations with any organization in the funding of this study."

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Response: "This has been captured in the updated Competing Interests Statement above.”

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Response: The updated funding statement is as indicated above. The updated Competing Interests Statement is as shown above.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Review Comments to the Author

Reviewer #1:

1. Abstract, methods: You stated the performed tests was “to eliminate possible confounding conditions”, but I think it was rather to select apparently healthy individuals. In addition, this section did not include other major components of methods and materials section like study period, sampling technique, statistical tools, etc.

Responses –

- “to eliminate possible confounding conditions” has been replaced with “restrict our study population to apparently healthy participants.”.

- Study period - The study period for this study is included in the method section of the manuscript (This was a cross-sectional study in which data was collected between March and October 2014, laboratory and data analyses were completed in 2018)

- Sampling technique – The sampling technique has been added to the abstract and now reads “It was a total study among volunteers for military service”

- Statistical tools – The statistical tools used have been added to the abstract (frequencies, median, mid 95th percentile range with 2.5th and 97.5th percentiles as limits)

2. Abstract, results: The third statement is not relevant, better to remove it.

Response – The third statement in abstract result has been deleted

3. Sample size: I think your sample size was 6,169 not 8,505.

Response - The number of participants that consented to participate in this study were 7,797 (note correction above). However, only 6,169 were eligible following serological and other tests to eliminate those with prevalent health conditions in Nigeria, which are capable of affecting health indices (as stated in the 3rd sentence of the Methods section of the Abstract).

4. Introduction (1st paragraph): Please combine the separately written idea as 1, 2, 3, 4. The message is similar.

Response¬ – Correction effected

5. Introduction (paragraph 2, line 6). Are you confident to conclude as many African countries have established their own RI? Please justify your conclusion through evidence. There are some fragmented studies but it is difficult to conclude.

Response – The sentence has been modified and now reads – ”However, studies from African countries are fragmented with no nationally established reference intervals….(8-15)”

6. Introduction: This portion did not clearly show the gap (such as factors affecting RI not included). Is national RI recommended in such multiethnic country like Nigeria?

Response – Nigeria has diverse ethnic groups with different cultural and social practices including varying economic classes. All these may affect dietary and developmental practices which can alter RIs. However, in accordance with studies from Western countries (such as the UK and the US), single RI values are used despite the fact that different races exist. Nigeria has a diverse social, cultural, environmental, dietary and economic practices which may affect RI in addition to prevalent health conditions in the country. Apart from the health conditions, these other variables that may affect RI could not be explored.

7. Materials and methods: You have to follow scientifically accepted guidelines in order to recruit apparently healthy participants. There is no sampling technique mentioned in the document. How did you check the data distribution and partition?

Response – This was a total population study among applicants for military service. No probability sampling was done in the wider source population nor from the participants as all of them were considered eligible subject to granting informed consent. Some of the participants that had bio-markers for known pathologies/conditions were excluded. We used a non-parametric analytic method to generate estimates and associated intervals. These methods do not need an assumption of normal distribution. We did not partition the data and we used a common reference interval for each analyte in both males and females as there was no statistically significant difference in the RIs.

Two new sentences were included to capture the idea more correctly. The inclusion criteria was also changed to exclusion criteria.

8. Result: The first paragraph should be removed and incorporated in materials and methods section.

Response –

The first paragraph in the results section has been incorporated into methods section. An introductory sentence on the final number of participants studied was added to the results.

9. Result, 2nd paragraph, last statement and 3rd paragraph, 4th and 5ith statement: Interpretation of data is not recommended. Data should be interpreted in the discussion section.

Response – This observation is noted and the statements have been moved to the discussion section as suggested.

10. Result: I think the RI of females is dominated by males due to large sample size. How could you justify this?

Response – The recommended CLSI minimum sample size standards for RI is 120 individuals per sub-group of a grouping variable. This study population exceeded this required minimum. This study was non-interventional and statistical comparison by gender was not done. Therefore, balance between the two groups was not necessary.

11. Result: Table 3&4: You try to compare your result with American and British studies only. You have to include studies in Africa, Asia, Latin, Etc. Besides, the American study is a text book study which is not appropriate. What was your base (statistics) for comparison? it is not included in materials and methods section.

Response - In Nigeria, due to lack of locally generated national RIs, like in most African countries, our clinical result interpretations are based on Western figures mainly represented by British and American values.. This was the reason for comparison with Western figures and why we did not consider it necessary to compare with Asian and Latin American values. However, we have included RIs from Ghana, West Africa. There was no statistical comparison between the other countries’ RIs and this study as the primary data set for the countries were not available to us. The American RIs from the Tietz textbook are a compilation of values from individual studies published in peer-reviewed journals. No attempt was made to statistically compare our findings with these textbook values. We only eyeballed our study’s RIs with those that are currently in clinical use in our environment. This was to ascertain the suitability of these foreign values for our clinical use.

12. Discussion: Which statistics you computed indicated to say ‘wider’, ‘lower’, ‘higher’ and ‘in concordance’? The discussion section is not supported by statistics and evidences done worldwide.

Response: The second sentence of the discussion states that our values APPEAR to be “wider”, “lower” and “higher” when juxtaposed with western values. By this, we do not imply statistically assessed relationships. This study, like has been mentioned was purely descriptive and involved only eyeballing.

13. Conclusion: It is out of your result.

Response: The conclusion has been adjusted to reflect the reviewer’s comments as advised.

Reviewer #2: I congratulate the authors for established RIs for Nigerian Adults and have country specific RIs. However, I do have a few comments for the authors which I believe will improve the manuscript.

Abstract:

Reference intervals are not quantitative data. These are assessment tool to interpret test results.

Response: Correction has been effected and the sentence has been modified

Please mention the number of analytes for which reference intervals were established and age of the participants clearly in the objective instead of "young Nigerian Adults".

Response: This has been addressed and the number of analytes (24) have been included as well as the age group.

In the method, the authors mentioned that the samples were drawn form 36 state and Territory. However, in the methods section of the paper, the authors mentioned that these participants were volunteers who applied for military services. So the samples were not drawn? Please be consistent.

Response:

The word “drawn” has been deleted and a new sentence “It was a total study among volunteers for military service” has been added.

Please revise the sentence "RIs of common clinical biochemistry analytes were computed." to "RIS were estimated using nonparametric methods."

Response: Correction effected.

Results. "No statistical comparison was made" should be in the methods. This is not a result.

Response: The sentence has been moved to methods

Introduction:

This is now well established that RIs are not an indicator of good health or disease unlike clinical decision limit. RIs simply indicate that certain percentage of people within a range. The comment made in the abstract about quantitative data also apply. Please revise the 1st sentence.

Response: The correction has been effected

How is the volunteers who applied for military service representative of the 18 - 26 year population in Nigeria?

Response: Studies conducted using volunteers are liable to experience the ‘healthy volunteer effect/bias’. This would have played some role in this study as military applicants are expected to be generally fitter and ‘more’ healthy. However, we do not perceive this to significantly alter our findings. We have also acknowledged this limitation in the discussion section of the paper.

What is the justification of comparing the RIs with western cohorts in Europe and North America but not the RIs currently used in Nigeria?

Response: In Nigeria, due to lack of locally generated national RIs, like in most African countries, our clinical result interpretations are based on Western figures mainly represented by British and American values. This is also mentioned in the first sentence of the last paragraph of the introduction.

Methods:

The description of Nigeria may not be necessary as part of the Study Area. Instead of total population I would report the 18 - 26 years old population to who these RIs are applicable.

Response:

The study area has been modified to reflect the population of interest in this study. We also deleted information about Nigeria that may not be necessary as advised.

I don't think the study was design prospectively and desired number of sample was determined. In fact, the study used the data available from the screening process. So the sample size determination may not be appropriate. I would advise the authors to move this point to the discussion expressing that you have more sample than what is recommended.

Response: The sub-heading ‘Sample size determination’ has been deleted and the content of that sub-section has been merged with the study design and study population section.

Biochemical Analysis: Please mention the analytical principle used for each of these biomarkers either as part of the paper or as supplementary. This information will be use for the laboratories who wish to use the RIs knowing there is variation in reference values between analysers/instruments.

Response: A table indicating the analytical principles for each biomarker has been added to the biochemical analysis section under Methods.

Statistical analysis:

Have the authors excluded any outliers? If yes, please explain what method was applied. If not, please justify who not. This is an important step of the statistical analysis.

Response: We did not assess the data for outliers, based on the fact that the participants had been screened earlier for prevalent health conditions that may account for out-of-range values. The data was carefully cleaned and no extreme values were observed during the process.

The authors should clearly mention what method was used for analysis. Measures of Central Tendency include Mean, Median, Mode etc. and deviation can be range, SD, Variance etc. I understand the authors have used median and 2.5th and 97.5th centile which is defined as nonparametric method by CLSI. So this should be clearly mentioned.

Response: This section has been modified and the 3rd sentence in the section now reads – “Non-parametric method of analysis was used to generate the measure of central tendency (median) and dispersion (2.5th – 97.5th range) for each biochemical parameter.”

Please report the 95% CIs of the RIs. This has also been recommend in recent publications.

Response: The calculation of CI around reference limits is based on an assumption of random sampling and this was not fulfilled in this study.

What method was applied to compare the established RIs with western countries? Visual? by considering with 95% CI of the established RIs include western countries' RIs?

Response: The comparison with Western values was visual and did not involve any analytical statistics

Results:

Why the auto-analyser could not provide results for all parameters?

Response: The auto-analyzer could not provide the results for all parameters in all the specimens despite repeated runs. We did not use manual techniques to prevent inconsistencies with the study protocol.

Considering the biochemistry analytes are associated with age in the paediatric population i.e. age 0 - <18, is there any association with age? The authors should include scatter plot of analytes across age by sex in the supplementary for the readers to understand age-specific RIs were not necessary for the young adult.

Response: It has been variously established over time that among young adults of the age range in our study, values of the assessed analytes do not vary with age. For this reason, we have not generated age-specific RIs. We therefore do not consider presentation of scatter plots necessary.

One of the concern I have is the unequal distribution of sexes in the sample. Overall only 237 samples were female. Hence, the RIs of male will be more precise compared to female.

Response: The recommended CLSI minimum sample size standards for RI is 120 individuals per sub-group of a grouping variable. The RIs generated for males will be more precise than the females even though the female values meet the minimum requirement for precision. This does not affect the validity of the generated RIs in females for clinical use.

Discussion & Conclusion: While the authors advocate for similar studies, validation or comparison of flagging rate would be another important step in ensuring the RIs are adopted by local laboratories.

Response: The Defence Reference Lab where the sample analysis was conducted is internationally accredited by A2LA. This means equipment, reagents, personnel proficiency, external quality assessments and other QA procedures are carried out as necessary. A new concluding sentence has been added to the conclusion to capture this suggestion.

Thank you very much for your time and I look forward to a feedback after review.

OR AYEMOBA

Brig Gen (rtd)

Corresponding Author

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Ulrike Gertrud Munderloh

11 Feb 2021

Reference intervals of common clinical biochemistry analytes in young Nigerian adults

PONE-D-20-25237R1

Dear Dr. Ayemoba,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ulrike Gertrud Munderloh, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The authors have addressed all the comments. I have no further comments. However, I would encourage the authors to read the manuscript carefully for typo and grammatical errors. I feel some sentences could be expressed better.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Acceptance letter

Ulrike Gertrud Munderloh

19 Feb 2021

PONE-D-20-25237R1

Reference intervals of common clinical biochemistry analytes in young Nigerian adults

Dear Dr. Ayemoba:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ulrike Gertrud Munderloh

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Author list and contributions.

    (DOCX)

    S2 File. Biochemistry dataset.

    (SAV)

    S3 File. MODHREC approval—Jan 2014.

    (PDF)

    S1 Appendix. Consent form.

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES